



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/563,465	01/05/2006	Giuseppe Giannini	2818-254	1374

23117 7590 04/26/2007
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203

EXAMINER

CHENG, KAREN

ART UNIT	PAPER NUMBER
----------	--------------

1626

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
31 DAYS	04/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary	Application No. 10/563,465	Applicant(s) GIANNINI ET AL.	
	Examiner Karen Cheng	Art Unit 1626	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-17 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-17 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|--|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ____ | 6) <input type="checkbox"/> Other: ____ |

DETAILED ACTION

Claims 1-17 are currently pending in this application and subject to the following restriction requirement.

Lack of Unity Requirement

Claims 1-17 are drawn to more than one inventive concept (as defined by PCT Rule 13), and accordingly, a restriction is required according to the provision set forth in PCT Rule 13.2.

PCT Rule 13.2 states that the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (requirement of unity of invention). PCT Rule 13.2 further states unity of invention as referred to in PCT Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. Special technical features, as defined in PCT Annex B, Part 1(b), include those technical features which define a contribution over the prior art.

PCT Annex B, Part 1(e) provides combinations of different categories of claims and states:

"The method for determining unity of invention under Rule 13.2 shall be construed as permitting, in particular, the inclusion of any one of the following combinations of claims of different categories in the same international application:

- (i) in addition to an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product, and an independent claim for a use of the said product, or


Art Unit: 1626

(ii) in addition to an independent claim for a given process, an independent claim for an apparatus or means specifically designed for carrying out the said process, or

(iii) in addition to an independent claim for a given product, an independent claim for a process specially adapted for the manufacture of the said product and an independent claim for an apparatus or means specifically designed for carrying out the said process,..."


This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. Due to numerous and widely divergent variables in the compound of Formula (I) for example: R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , etc., a precise listing of inventive groups cannot be made. The following Groups are exemplary:

Group I: Claims 1-2 and 11 drawn to compounds of formula (I)




the rest of the variables are as defined.

Group II: Claims 1-2 and 11 drawn to compounds of formula (I)




Art Unit: 1626

Group III: Claims 1-2 and 11 drawn to compounds of formula (I)




and the rest of the variables are as defined.

Group IV: Claims 1-2 and 11 drawn to compounds of formula (I)




and the rest of the variables are as defined.

Group V: Claims 1-2 and 11 drawn to compounds of formula (I)




Z is CH, and the rest of the variables are as defined.

Group VI: Claims 1-2 and 11 drawn to compounds of formula (I)




Z is N, and the rest of the variables are as defined.



Group VII: Claims 1-2 and 11 drawn to compounds of formula (I)



Group VIII: Claims 1-2 and 11 drawn to compounds of formula (I)




Group IX: Claims 3-10 drawn to a method of use of compounds of formula (I) as medicaments; medicaments for treatment of oncological-type diseases; treatment of cancers that respond to cytotoxic activity including sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, etc; treatment of diseases related to abnormal angiogenesis including arthritic disease, diabetic retinopathy, etc by administration of a



and the rest of the variables are as defined.



Group X: Claims 3-10 drawn to a method of use of compounds of formula (I) as medicaments; medicaments for treatment of oncological-type diseases; treatment of cancers that respond to cytotoxic activity including sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, etc; treatment of diseases related to abnormal angiogenesis including arthritic disease, diabetic retinopathy, etc by administration of a




the rest of the variables are as defined.


Group XI: Claims 3-10 drawn to a method of use of compounds of formula (I) as medicaments; medicaments for treatment of oncological-type diseases; treatment of cancers that respond to cytotoxic activity including sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, etc; treatment of diseases related to abnormal angiogenesis including arthritic disease, diabetic retinopathy, etc by administration of a

Art Unit: 1626


compound of formula (I)  wherein Y is , Ar is

, X is O, Z is CH, and the rest of the variables are as defined.



Group XII: Claims 12 and 13 drawn to compounds of formula

 wherein R is H, methyl or tert-butyl-dimethylsilyl.


Group XIII: Claim 14 drawn to compounds of formula

 wherein the variables are as defined.

Group XIV: Claims 15-16 drawn to compounds of formula

 and 

Group XV: Claim 17 drawn to compounds of formula

. Note that R is not defined in this claim.


And etc.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted. Again this list is not exhaustive as it would be impossible to write out all groups under the time constraints due to the sheer volume of subject matter instantly claimed. Therefore, applicant may choose to elect a single invention (a product or a process of preparation or a method of use) by identifying another specific embodiment of similar scope not listed in the exemplary groups of the invention and examiner will endeavor to group the same. The applicant may also choose to elect a single disclosed species or a single disclosed species for a single method of use or preparation and the examiner will endeavor to create a group comprising the elected species.

The claims herein lack unity of invention under PCT Rules 13.1 and 13.2 since under 37 CFR 1.475:

Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical feature among those inventions involving one or more of the same or corresponding special technical features...those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.

Groups I-XV lack unity of invention because, pursuant to 37 CFR 1.475(a), there is no structural moiety common to all the Groups as defined. Additionally, Kim *et al* disclose compounds that contain the structural moiety common to **Groups I-XI**



(see Chem. Pharm. Bull., Vol. 51(5), 2003, p. 516-521). Therefore

Claims 1-17 are not so linked as to form a single general inventive concept, and there is

lack of unity of invention. The variables vary extensively and, when taken as a whole, result in vastly different compounds. Additionally, the vastness of the claimed subject matter and the complications in understanding the claimed subject matter impose a serious burden on any examination of the claimed subject matter.

Because the claims do not relate to a single general inventive concept under PCT Rule 13.1 and lack the same or corresponding special technical features, the claims lack unity of invention and should be limited to a product, a process for the manufacture of said product, **or** a method of use.

As a result, if Group IX-XI or any Group drawn to methods of uses is elected then election of a specific method of use is required: for example, a method of treating

- A. bone cancer,
- B. arthritic disease,
- C. diabetic retinopathy, etc.

Furthermore, with respect to **Groups I-XV**, even if unity of invention under 36 CFR 1.475(a) is not lacking, a national stage application, under 37 CFR 1.475(b), containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn to only one of the following combinations:

- (1) A product and a process specially adapted for the manufacture of said product; or
- (2) A product and process of use of said product; or
- (3) A product, a process specially adapted for the manufacture of said product, and a use of said product; or
- (4) A process and an apparatus or means specially designed for carrying out said process; or
- (5) A product, a process specially adapted for the manufacture of said product, and an apparatus or means specially designed for carrying out said process.

Moreover, according to 37 CFR 1.475(c), if an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b), unity of invention might not be present.

In the instant case, the claims are drawn to multiple products and more than one process of use of said product. According to 37 CFR 1.475(e),

The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.


Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Conclusion


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cheng whose telephone number is 571-272-6233. The examiner can normally be reached on M-F, 9AM to 5:30PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane can be reached on (571)272-0699. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



Karen Cheng
Patent Examiner, AU 1626

KAMAL A. SAEED, PH.D.
PRIMARY EXAMINER

for Joseph McKane
Supervisory Patent Examiner, AU 1626